GLP-1 drugs
Lilly's tirzepatide wins approval in China
Eli Lilly's weight loss drug tirzepatide — sold under the name Zepbound — just won regulatory approval in China, intensifying competition with Danish rival Novo Nordisk in the key Asian market, Reuters writes.
Novo's competing weight loss drug, Wegovy, was approved in China just last month. Both Lilly and Novo are now working to increase production to meet the growing demand in a global weight loss market expected to reach $100 billion by the end of the decade.
pBMs
Express Scripts overcharged postal workers by $45 million
A federal audit showed that Express Scripts, one of the largest pharmacy benefit managers, overcharged U.S. Postal Service employees by $45 million for prescription drugs between 2016 and 2021, primarily by withholding drug rebates meant for the health plan.
The audit provides timely fodder for federal lawmakers, who will grill top PBM executives this week in front of the House Committee on Oversight and Accountability, STAT's Bob Herman and Ed Silverman write.
Read more.
No comments